Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant-Reference-Cited by-同舟云学术

Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant

Published:2022-02-02 Issue:2 Volume:197 Page:212-222
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Savani Malvi¹^ORCID,Ahn Kwang W.²³,Chen Yue³,Ahmed Sairah⁴^ORCID,Cashen Amanda F.⁵,Shadman Mazyar⁶,Modi Dipenkumar⁷⁸^ORCID,Khimani Farhad⁹,Cutler Corey S.¹⁰,Zain Jasmine¹¹,Brammer Jonathan E.¹²,Rezvani Andrew R.¹³,Fenske Timothy S.¹⁴,Sauter Craig S.¹⁵,Kharfan‐Dabaja Mohamed A.¹⁶,Herrera Alex F.¹¹,Hamadani Mehdi³¹⁴^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine University of Arizona and University of Arizona Cancer Center Tucson Arizona USA

2. Division of Biostatistics, Institute for Health and Equity Medical College of Wisconsin Milwaukee Wisconsin USA

3. Department of Medicine, Center for International Blood and Marrow Transplant Research Medical College of Wisconsin Milwaukee Wisconsin USA

4. Division of Cancer Medicine, Departments of Lymphoma/Myeloma and Stem Cell Transplantation University of Texas MD Anderson Cancer Center Houston Texas USA

5. Division of Oncology, Department of Medicine Washington University School of Medicine Saint Louis Missouri USA

6. Department of Medicine University of Washington, Fred Hutchinson Cancer Research Center Seattle Washington USA

7. Department of Oncology Karmanos Cancer Institute, Wayne State University Detroit Michigan USA

8. Division of Hematology‐Oncology Karmanos Cancer Institute, Wayne State University Detroit Michigan USA

9. Department of Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

10. Department of Stem Cell Transplantation and Cellular Therapy Dana‐Farber Cancer Institute Boston Massachusetts USA

11. Department of Hematology and Hematopoietic Stem Cell Transplantation City of Hope National Medical Center Duarte California USA

12. Division of Hematology, Department of Medicine Ohio State University Columbus Ohio USA

13. Division of Blood & Marrow Transplantation, Department of Medicine Stanford University Stanford California USA

14. BMT & Cellular Therapy Program, Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

15. Department of Medicine Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York New York USA

16. Division of Hematology‐Oncology and Blood and Marrow Transplantation Program Mayo Clinic Jacksonville Florida USA

Funder

National Heart, Lung, and Blood Institute

StemCyte

Sanofi Genzyme

Pharmacyclics

Novartis Pharmaceuticals Corporation

Miltenyi Biotec

Takeda Pharmaceutical Company

Merck Sharp and Dohme

Kyowa Hakko Kirin

Kite Pharma

Kiadis Pharma

Jazz Pharmaceuticals

Johnson and Johnson

Janssen Pharmaceuticals

Incyte

Genentech

Daiichi-Sankyo

Fonds de dotation CSL Behring pour la recherche

Bristol-Myers Squibb

bluebird bio

Astellas Pharma US

Angiocrine Bioscience

Medical College of Wisconsin

Be The Match Foundation

Office of Naval Research

Health Resources and Services Administration

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18052

Reference39 articles.

1. Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

2. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

4. Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

5. Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced‐intensity conditioning with fludarabine/busulfan versus fludarabine/low‐dose melphalan in patients with non‐Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation;British Journal of Haematology;2024-07-24

2. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma;Expert Review of Anticancer Therapy;2024-01-26

3. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-01

4. Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas;Blood Journal;2023-12-25

5. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source;Transplantation and Cellular Therapy;2023-04